Vanda is probably one of the higher potential reward stocks in this recent purchase spree.
As mentioned, I had invested in them way back in (2014?) when they got approval for 24 hour sleep pattern disorder but had not been in the stock since then.
Interesting to me is their phase III drug Tradipitant (where do they come up with drug names?). It is being used to treat gastroparesis, which is really widespread. Sounds super great except they got into a spat with the FDA over animal testing (the FDA wanted a longer testing period for toxicity in a number of different animals). They actually sued the FDA. You know what usually happens when you sue the government? Yeah...you lose.
But anyway, it seems a number of patients that were taking Tradipitant for the max 3 month trial period allowed without the longer toxicity tests have appealed to the FDA to be allowed to continue taking it, calling it life changing. To me, if a drug is being clamored for by patients, and it isn't morphine based, that is a potential seller.
So they have revenues from two drugs of about 250 million a year, they eek out a small profit from this despite the other drug trials, they have over 300 million in cash, and they have a 500 million dollar market cap.
Yeah. Interesting for sure.